Who is the manufacturer of EMPHASYS Femoral Stems?

Depuy Ireland UC filed the 510(k) submission for EMPHASYS Femoral Stems (K211657).

What is the FDA product code for EMPHASYS Femoral Stems?

LZO. It is classified under 21 CFR 888.3353 as a Class 2 device in the Orthopedic panel.

What is the regulatory pathway for EMPHASYS Femoral Stems?

510(k) clearance (submission type: Traditional).

What are the predicate devices for EMPHASYS Femoral Stems?

DePuy Corail AMT Hip Prosthesis (K190344); Corail AMT Hip Prosthesis (K042992); DePuy Corail AMT Hip Prosthesis (K123991); DePuy Corail AMT Hip Prosthesis (K173960); DePuy Corail AMT Hip Prosthesis (K192946); Summit Hip System (K001991); Summit Hip System (K170339); Actis DuoFix Hip Prosthesis - Collarless (K210581).

Who can help prepare an FDA 510(k) submission like EMPHASYS Femoral Stems?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

EMPHASYS Femoral Stems

K211657 · Depuy Ireland UC · LZO · Aug 5, 2021 · Orthopedic

Device Facts

Record ID	K211657
Device Name	EMPHASYS Femoral Stems
Applicant	Depuy Ireland UC
Product Code	LZO · Orthopedic
Decision Date	Aug 5, 2021
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 888.3353
Device Class	Class 2
Attributes	Therapeutic

Intended Use

Total and Hemi Hip Arthroplasty

Device Story

EMPHASYS Femoral Stems are orthopedic implants used in total or hemi-hip arthroplasty. The device consists of HA-coated femoral stems available in standard/high offsets and collared/collarless configurations. It is designed for use with modular femoral heads (metal, dual mobility, or ceramic) and acetabular components (total hip) or modular unipolar/bipolar heads (hemi-hip). The device is implanted by a surgeon in a clinical setting to replace damaged or diseased hip joint components. By providing a stable, biocompatible femoral component, the device restores joint function, reduces pain, and improves mobility for patients suffering from degenerative or traumatic hip conditions.

Clinical Evidence

No clinical tests were conducted. Substantial equivalence was demonstrated through non-clinical bench testing, including neck and distal stem fatigue (ISO 7206), range of motion (ISO 21535), biocompatibility (ISO 10993), and MRI safety (ASTM F2503).

Technological Characteristics

Forged titanium alloy femoral stems with hydroxyapatite (HA) coating. Features include standard/high offsets, collared/collarless configurations, and 130° neck angle. Modular design compatible with various femoral heads and acetabular components. Testing standards: ISO 7206-6 (neck fatigue), ISO 7206-4 (distal stem fatigue), ISO 21535 (range of motion), ISO 10993 (biocompatibility), ANSI/AAMI ST 72 (endotoxin), and ASTM F2503/F2213/F2119/F2182 (MRI safety).

Indications for Use

Indicated for total hip replacement in patients with severely painful/disabled joints due to osteoarthritis, traumatic arthritis, rheumatoid arthritis, congenital hip dysplasia, avascular necrosis of the femoral head, acute traumatic fracture of the femoral head/neck, failed previous hip surgery (reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement, or total hip replacement), or ankylosis. Indicated for partial hip replacement in patients with acute fracture of the femoral head/neck or fracture dislocation of the hip that cannot be reduced/treated with internal fixation, avascular necrosis of the femoral head, non-union of femoral neck fractures, high subcapital/femoral neck fractures in the elderly, degenerative arthritis of the femoral head only, or pathology of the femoral head/neck/proximal femur treatable by hemiarthroplasty.

Regulatory Classification

Identification

A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.

Predicate Devices

DePuy Corail AMT Hip Prosthesis (K190344)
Corail AMT Hip Prosthesis (K042992)
DePuy Corail AMT Hip Prosthesis (K123991)
DePuy Corail AMT Hip Prosthesis (K173960)
DePuy Corail AMT Hip Prosthesis (K192946)
Summit Hip System (K001991)
Summit Hip System (K170339)
Actis DuoFix Hip Prosthesis - Collarless (K210581)

Related Devices

K173794 — AMIStem-H Proximal Coating, AMIStem-P and AMIStem-P Collared · Medacta International S.A. · Mar 14, 2018
K954598 — OSTEONICS OFFSET HIP STEMS · Osteonics Corp. · Apr 4, 1996
K252401 — implaFit® short stems · Implantcast GmbH · Mar 12, 2026
K021403 — HA MALLORY/HEAD POROUS FEMORAL STEM & HA MALLORY/HEAD POROUS LATERALIZED FEMORAL STEM · Biomet Orthopedics, Inc. · May 31, 2002
K993027 — ESKA MODULAR HIP SYSTEM · Specs USA, Inc. · Apr 6, 2000

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. August 5, 2021 DePuy Ireland UC % Clare Hill Senior Manager, Regulatory Affairs, CRO Regulatory Affairs DePuy Synthes, IRenc. 700 Orthopaedic Drive Warsaw, Illinois 46582 Re: K211657 Trade/Device Name: EMPHASYS Femoral Stems Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, KWL, KWL, KWY, MEH Dated: May 27, 2021 Received: May 28, 2021 Dear Clare Hill: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Limin Sun Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration ## Indications for Use 510(k) Number (if known) K211657 Device Name EMPHASYS Femoral Stems Indications for Use (Describe) #### INDICATIONS Total hip replacement is indicated in the following conditions: 1. A severely painful and/or disabled joint from osteoarthritis, rheumatoid arthritis, or congenital hip dysplasia. 2. Avascular necrosis of the femoral head. 3. Acute traumatic fracture of the femoral head or neck. 4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, surface replacement arthroplasty, or total hip replacement. 5. Certain cases of ankylosis. Partial hip replacement is indicated in the following conditions: 1. Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated fixation. 2. Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation. - 3. Avascular necrosis of the femoral head. - 4. Non-union of femoral neck fractures. 5. Certain high subcapital and femoral neck fractures in the elderly. 6. Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement. 7. Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemiarthroplasty. | Type of Use (Select one or both, as applicable) | | | |-------------------------------------------------|---------------------------------------------|--| | X Prescription Hos (Dart 21 CED 801 Subnart D) | Over-The-Counter Use (21 CED 801 Subnart C) | | ## CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ # 510(K) SUMMARY (As required by 21 CFR 807.92 and 21 CFR 807.93) | Submitter Information | | |---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Name | DePuy Ireland UC | | Address | Loughbeg, Ringaskiddy Co. Cork Munster, IRELAND | | Phone number | 574-404-8782 | | Establishment Registration Number | 1818910 | | Name of contact person | Clare Hill | | Date prepared | 25 May 2021 | | Name of device | | | Trade or proprietary name | EMPHASYS Femoral Stems | | Common or usual name | Total or Hemi-Hip Arthroplasty Prosthesis | | Classification name | Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented Prosthesis, Hip, Hemi-, Femoral, Metal Prosthesis, Hip, Hemi-, Femoral, Metal/Polymer, Cemented Or Uncemented Prosthesis, Hip, Semi-Constrained, Uncemented, Metal / Polymer, Non- Porous, Calcium Phosphate | | Class | II | | Classification panel | 87 Orthopedics | | Regulation | 21 CFR 888.3353: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis 21 CFR 888.3360: Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis 21 CFR 888.3390: Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis | | Product Code(s) | LZO, KWL, KWY, MEH | | Legally marketed device(s) to which equivalence is claimed | DePuy Corail AMT Hip Prosthesis (K190344) – Primary predicate Corail AMT Hip Prosthesis (K042992) DePuy Corail AMT Hip Prosthesis (K123991) DePuy Corail AMT Hip Prosthesis (K173960) DePuy Corail AMT Hip Prosthesis (K192946) Summit Hip System (K001991) | | | Summit Hip System (K170339) | | | Actis DuoFix Hip Prosthesis - Collarless (K210581) | | Reason for 510(k) submission | The purpose of this submission is to obtain market clearance for the EMPHASYS Femoral Stems, one component of a system of prostheses used in hip arthroplasty. | | Device description | The EMPHASYS Femoral Stems include HA-coated femoral stems in standard and high offsets and in collared and collarless configurations. The EMPHASYS Femoral Stems are designed to be used as one component of a system of prostheses in hip arthroplasty. The stems are compatible with a DePuy modular metal, dual mobility, or ceramic femoral head, and either a one-piece or a metal-backed two-piece acetabular component for use in total hip arthroplasty, and with a modular unipolar metallic femoral head or a modular bipolar head construct for hemi-hip arthroplasty. | | Intended use of the device | Total and Hemi Hip Arthroplasty | | Indications for use | Total hip replacement is indicated in the following conditions: 1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia. 2. Avascular necrosis of the femoral head. 3. Acute traumatic fracture of the femoral head or neck. 4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement. 5. Certain cases of ankylosis. Partial hip replacement is indicated in the following conditions: 1. Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation. 2. Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation. 3. Avascular necrosis of the femoral head. 4. Non-union of femoral neck fractures. 5. Certain high subcapital and femoral neck fractures in the elderly. 6. Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement. 7. Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemiarthroplasty. | {4}------------------------------------------------ {5}------------------------------------------------ ## SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO THE PREDICATE DEVICE The subject EMPHASYS Femoral Stems are similar to the predicate CORALL AMT Hip Prosthesis (K042992, K123960, K190344) in intended use, indications for use, design. The subject and predicate systems are intended for total or hemi hip arthroplasy and have the same indications for use. Both are forged titanium alloy. HA coated stems for uncemented use with a taper. Both devices have the same size tapers, and both are offered in collaress, standard offset and high offset configurations. Both devices are used in a modular hip construct which includes DePuy femoral head and acetabular components. The design of the subject and predicate devices is similar in terms of shape and function the intraosseous geometry of the subject devices has a narrower ML profile in places and is shorter than the predicate stems. The subject devices are offered in a 130° neck angle that is in between the two angles offered by the predicate devices. #### PERFORMANCE DATA ## SUMMARY OF NON-CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE Testing and engineering analyses were performed on the EMPHASYS Femoral Stems to demonstrate substantial equivalence of safety and efficacy with the predicate device, addressing: - Neck Fatigue (to ISO 7206-6: 2013) . - Distal Stem Fatigue (to ISO 7206-4: 2010) . - Range of Motion (to BS EN ISO 21535: 2009) . - Taper equivalence Biocompatibility evaluation was carried out to ISO 10993-1:2018 and testing was carried out to include genotoxicity to ISO 10993-3:2014, cytotoxicity to ISO 10993-5:2009, sensitization to ISO 10993-10:2010, pyrogenicity to ISO 10993-11:2017 and chemical characterization to ISO 10993-18:2020. The proposed devices also meet the requirement of bacterial endotoxin testing as specified in ANSI/AAMI ST 72:2019. Magnetic Resonance Imaging safety evaluation testing was performed following ASTM F2503-13, and the tests evaluated the worst-case components and constructs for magnetically induced force (ASTM F2213-17), image artefact (ASTM 2119-07 (reapproved 2013)) and RF heating (ASTM F2182-19). The testing concluded that there are no safety issues related to magnetic field interactions under specific conditions identified in the labelling. Hydroxyapatie characterization data, as recommended in the FDA Guidance 510(k) Information needed for Hydrosyapatite coated Orthopedic Implants, is provided. ## SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICAL INFORMATION No clinical tests were conducted to demonstrate substantial equivalence. ### CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA The subject EMPHASYS Femoral Stems are substantially equivalent to the predicate CORAIL AMT Hip Prosthesis.